Physician
Dana-Farber Cancer Institute, INC.
Dana-Farber Cancer Institute, INC. was paid $4.81M by Medicaid between Mar 2018 and Sep 2024, across 74 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 15% of everything it billed.
33Billing provider infoDANA-FARBER CANCER INSTITUTE, INC.
BOSTON, MA 02115
BOSTON, MA 02115
33aNPI1346433257assigned 08/23/2007
33bProvider typeMedical Oncology Physician
28Total paid$4.81M
24GClaims32,496
24DCodes billed74
24AFirst – last monthMar 2018 – Sep 2024
Compared with peers
Next to other Medical Oncology Physician providers in Massachusetts
Rank by total paid#1 of 10
Median peer was paid$8K
This provider vs. median639×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 13,607 | $2.15M | |
| 2019 | 16,565 | $2.55M | |
| 2020 | 68 | $2K | |
| 2021 | 416 | $7K | |
| 2022 | 46 | $2K | |
| 2023 | 1,382 | $79K | |
| 2024incomplete | 412 | $21K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 15% | 2,633 | 1,704 | $710K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 14% | 1,788 | 905 | $677K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 8.6% | 2,027 | 1,454 | $414K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 7.3% | 1,336 | 1,160 | $349K |
| 96375 | Therapeutic injection; each additional sequential IV push | 7.1% | 1,133 | 620 | $343K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.3% | 1,059 | 912 | $255K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.5% | 122 | 122 | $217K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.8% | 3,073 | 2,072 | $184K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 3.2% | 221 | 221 | $153K |
| 96411 | 3.1% | 612 | 416 | $151K | |
| 80050 | General health panel | 3.0% | 368 | 312 | $144K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 2.8% | 448 | 402 | $134K |
62 more codes
| 96417 | 2.4% | 472 | $118K | |
| 96409 | 2.0% | 440 | $96K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.7% | 258 | $82K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.2% | 278 | $55K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | 1.1% | 1,290 | $55K |
| 83735 | 1.1% | 2,042 | $55K | |
| 86850 | 1.0% | 530 | $49K | |
| 96367 | <1% | 309 | $44K | |
| 96415 | <1% | 117 | $42K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 903 | $39K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 176 | $38K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 193 | $32K |
| 86900 | <1% | 570 | $30K | |
| 99205 | Prolong outpt/office vis | <1% | 80 | $28K |
| 84100 | <1% | 1,487 | $28K | |
| 86901 | <1% | 522 | $27K | |
| 82378 | <1% | 329 | $25K | |
| 85027 | <1% | 823 | $24K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 76 | $21K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 38 | $21K |
| 82248 | <1% | 1,220 | $20K | |
| 83615 | <1% | 707 | $17K | |
| 82784 | <1% | 157 | $16K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 111 | $14K |
| 99223 | Prolong inpt eval add15 m | <1% | 104 | $14K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 19 | $12K |
| 85007 | <1% | 786 | $12K | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 458 | $9K |
| 80076 | <1% | 48 | $6K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 66 | $6K |
| 84439 | <1% | 130 | $6K | |
| 82565 | <1% | 251 | $5K | |
| 82247 | <1% | 341 | $4K | |
| 90686 | <1% | 111 | $4K | |
| 84450 | <1% | 238 | $3K | |
| G0008 | Administration of influenza virus vaccine | <1% | 107 | $2K |
| 80051 | <1% | 29 | $2K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 457 | $2K |
| 81001 | <1% | 109 | $2K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 32 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 485 | $1K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 14 | $1K |
| 82310 | <1% | 50 | $1K | |
| 84520 | <1% | 58 | $1K | |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 13 | $1K |
| 83516 | <1% | 29 | $1K | |
| 81003 | <1% | 58 | $1K | |
| 84702 | <1% | 16 | $931.68 | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 30 | $682.24 |
| 82947 | <1% | 26 | $677.15 | |
| J3490 | Unclassified drugs | <1% | 23 | $667.92 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15 | $647.76 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 28 | $639.55 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 121 | $549.51 |
| 85045 | <1% | 32 | $493.00 | |
| 84132 | <1% | 24 | $488.75 | |
| 82374 | <1% | 23 | $397.91 | |
| 84295 | <1% | 19 | $363.47 | |
| 84550 | <1% | 16 | $299.20 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 99 | $173.92 |
| J9250 | Methotrexate sodium, 5 mg | <1% | 43 | $134.49 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 40 | $60.73 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDEMBINSKI, PAUL (SENIOR DIRECTOR OF PFS)
Parent organizationDANA-FARBER CANCER INSTITUTE, INC.
| Provider | Location | Paid |
|---|---|---|
| Dana-Farber Cancer Institute, INC. | Boston, MA | $240.21M |
| Dana-Farber Cancer Institute, INC. | Boston, MA | $24K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.